<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00712101</url>
  </required_header>
  <id_info>
    <org_study_id>Final version 1.1</org_study_id>
    <nct_id>NCT00712101</nct_id>
  </id_info>
  <brief_title>Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction</brief_title>
  <acronym>AIDA STEMI</acronym>
  <official_title>Prospective Randomized Controlled Clinical Study to Compare Abciximab-bolus i.v. Versus i.c. in Primary PCI in Patients With Acute ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether intracoronary abciximab bolus application
      with subsequent 12 hour intravenous infusion in addition to primary percutaneous coronary
      intervention is beneficial for patients with STEMI in comparison to standard i.v. bolus
      application with respect to 90-day mortality, reinfarction and new congestive heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with acute ST-elevation myocardial infarction (STEMI) primary percutaneous
      coronary intervention (PCI) is the preferred reperfusion regimen, if performed by experienced
      operators in a timely manner. Nevertheless, myocardial damage is not immediately terminated
      after successful epicardial reperfusion by primary PCI. Current strategies are directed to
      improve myocardial tissue perfusion, which is impaired in approximately 50% of patients and
      which has prognostic impact. Adjunctive intravenous abciximab administration is an
      established therapy to improve coronary microcirculation and reduce major cardiac adverse
      events.5-10 In randomized clinical trials intravenous abciximab administration has been
      studied. Clinical trials have shown that earlier administration results in higher
      preinterventional TIMI-flow with subsequent improved perfusion post PCI. However, in a pooled
      analysis there was no effect on mortality. As door-to-balloon-times getting shorter in
      current trials, earlier abciximab administration requires treatment in the prehospital
      setting, which poses substantial logistic obstacles. Another option might be intracoronary
      abciximab bolus administration which results in very high local platelet inhibitor
      concentrations. This might be favorable in dissolution of thrombi and microemboli with
      subsequent improved myocardial microcirculation, reduction of no-reflow, and infarct size.
      Currently, there is only limited clinical experience on the efficacy of intracoronary
      abciximab administration mainly restricted to case reports, retrospective registries or small
      randomized trials. In a recently published randomized clinical trial, we were able to show
      that intracoronary versus intravenous abciximab bolus administration has beneficial effects
      on the occurrence of no-reflow and infarct size assessed by contrast-enhancement magnetic
      resonance imaging. This led to a trend towards improved clinical outcome. The composite major
      adverse cardiac event rate, defined as death, reinfarction, target vessel revascularization,
      and new congestive heart failure, at 30 day follow-up was 15.6% after intravenous and 5.2%
      after intracoronary abciximab administration (relative risk 3.00; 95% confidence intervals
      0.94-10.80; p=0.06).

      Currently, there is no adequately powered clinical trial to assess the effects of
      intracoronary bolus in comparison to standard intravenous abciximab administration. Due to
      its general availability and its ease of intracoronary administration this treatment has
      overwhelming potential in clinical practice, which is much easier to achieve than a
      logistically cumbersome prehospital or interhospital transfer administration.

      In the era of evidence-based medicine, such a trial is of paramount importance to achieve a
      break-through in abciximab use and a reduction of the high associated morbidity and mortality
      of STEMI patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined clinical endpoint: death, reinfarction, new congestive heart failure</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution 90 minute ECG TIMI-flow post PCI indirect infarct size by enzyme release individual clinical endpoints</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1912</enrollment>
  <condition>ST-elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abciximab bolus administration intracoronary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abciximab bolus intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab intracoronary</intervention_name>
    <description>administer abciximab bolus intracoronary during primary percutaneous coronary intervention</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abciximab intravenously</intervention_name>
    <description>administer abciximab bolus intravenously during primary percutaneous coronary intervention</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical symptoms:

               -  Angina pectoris &lt; 12 hours and

               -  Persistent angina &gt; 30 minutes

          2. ECG-criteria for ST-elevation myocardial infarction in 12-lead ECG:

               -  ST-segment elevation &gt; 1mm in ≥ 2 extremity leads and/or

               -  ST-segment elevation &gt; 2mm in ≥ 2 adjacent precordial leads

          3. Informed consent

        Exclusion Criteria:

          1. No informed consent

          2. Pregnancy

          3. Known allergy to abciximab, ASA or heparin

          4. Active peptic ulcus ventriculi or duodeni

          5. Active, non-superficial bleeding

          6. History of major surgery (including intracranial or intraspinal) &lt;4 weeks

          7. active internal bleeding

          8. Cerebrovascular complications &lt; 2 years

          9. Known coagulation defect or thrombocytopenia

         10. Arteriovenous malformations or aneurysm

         11. Severe liver insufficiency, renal insufficiency requiring dialysis

         12. Uncontrolled hypertension, hypertensive retinopathy

         13. Vaskulitis

         14. Thrombolysis &lt; 12 h

         15. Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerhard Schuler, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Heartcenter Leipzig GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jochen Woehrle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäß-KLinik Bad Neustadt</name>
      <address>
        <city>Bad Neustadt</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz und Diabeteszentrum Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Links der Weser - Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig - Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl-von-Basedow-Klinikum Merseburg</name>
      <address>
        <city>Merseburg</city>
        <zip>06217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Pirna</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jochen Wöhrle</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Villingen-Schwenningen</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.</citation>
    <PMID>18559698</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2008</study_first_posted>
  <last_update_submitted>April 19, 2011</last_update_submitted>
  <last_update_submitted_qc>April 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Holger Thiele</name_title>
    <organization>University of Leipzig - Heart Center</organization>
  </responsible_party>
  <keyword>infarction</keyword>
  <keyword>intervention</keyword>
  <keyword>stent</keyword>
  <keyword>abciximab</keyword>
  <keyword>platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

